Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile

Authors :: Diletta Arcidiacono
Laura D'Erasmo
Sara De Martin
Nicola Ferri
Fabio Fimiani
Alice Zaramella
Angelo B. Cefalù
Maria Giovanna Lupo
Paolo Calabrò
Alberto Zambon
Maurizio Averna
Marcello Arca
Lupo, M. G.
Arcidiacono, D.
Zaramella, A.
Fimiani, F.
Calabro', P.
Cefalu, A. B.
Averna, M.
D'Erasmo, L.
Arca, M.
De Martin, S.
Zambon, A.
Ferri, N.
Lupo M.G.
Arcidiacono D.
Zaramella A.
Fimiani F.
Calabro P.
Cefalu AB
Averna M
D'Erasmo L.
Arca M.
De Martin S.
Zambon A.
Ferri N.
Source :: Atherosclerosis Plus, Vol 43, Iss, Pp 7-9 (2021)
Publication Year :: 2021
Publisher :: Elsevier B.V., 2021.
Abstract: Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Tools